Magnesium supplements for the treatment of resistant depression

The effect of 1600mg daily dosage of Magnesium supplementation as an augment to SSRI medication on the clinical symptoms of patients with treatment resistant depression: a pilot study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000574640

Enrollment

Registered

2014-05-29

Start date

2014-06-09

Completion date

2014-08-29

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study examines the role of Magnesium supplementation in depression that is resistant to standard treatment. 10 participants who have a confirmed history of treatment non-response while on Medication will be recruited into this small pilot study. participants will take a 1600mg a day divided Magnesium dose in addition to standard medication treatment for a maximum of 8 weeks following a standard protocol in which participants will be subject to pre and post clinical symptom measures. this study aims to provide a preliminary investigation of the value of Magnesium supplement adjuvant treatment for resistant depression.

Interventions

magnesium oral tablet supplement @1600mg daily in divided doses morning and evening with food for 8 weeks, in addition to prescribed SSRI medication participants recruited with a history of non-response to standard treatment pilot only target is n=10 dosage log provided for participants with weekly phone follow up to ensure dosage fidelity

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Participants should: 1. Be depressed, while taking SSRI antidepressant medication as prescribed by their doctor 2. Currently be under the management of a medical practitioner e.g. family doctor or a psychiatrist 3. Have a history of depression that has not responded well to medication, with at least 2 previous episodes 4. Be over 18 years of age and have the capacity to provide informed consent 5. Have the willingness and ability to comply with assessment protocols of the study

Exclusion criteria

1. Resistant depression not being the primary diagnosis 2. current substance misuse 3. other psychiatric disorder as primary diagnosis 4. active suicidality 5. not able to understand or conform to study requirements 6. Subject to a mental health or guardianship order

Outcome results